Literature DB >> 16806855

An integrated approach to model hepatic drug clearance.

Lichuan Liu1, K Sandy Pang.   

Abstract

It has been well accepted that hepatic drug extraction depends on the blood flow, vascular binding, transmembrane barriers, transporters, enzymes and cosubstrate and their zonal heterogeneity. Models of hepatic drug clearances have been appraised with respect to their utility in predicting drug removal by the liver. Among these models, the "well-stirred" model is the simplest since it assumes venous equilibration, with drug emerging from the outflow being in equilibrium with drug within the liver, and the concentration is the same throughout. The "parallel tube" and dispersion models, and distributed model of Goresky and co-workers have been used to account for the observed sinusoidal concentration gradient from the inlet and outlet. Departure from these models exists to include heterogeneity in flow, enzymes, and transporters. This article utilized the physiologically based pharmacokinetic (PBPK) liver model and its extension that include heterogeneity in enzymes and transporters to illustrate how in vitro uptake and metabolic data from zonal hepatocytes on transport and enzymes may be used to predict the kinetics of removal in the intact liver; binding data were also necessary. In doing so, an integrative platform was provided to examine determinants of hepatic drug clearance. We used enalapril and digoxin as examples, and described a simple liver PBPK model that included transmembrane transport and metabolism occurring behind the membrane, and a zonal model in which the PBPK model was expanded three sets of sub-compartments that are arranged sequentially to represent zones 1, 2, and 3 along the flow path. The latter model readily accommodated the heterogeneous distribution of hepatic enzymes and transporters. Transport and metabolic data, piecewise information that served as initial estimates, allowed for the unknown efflux and other intrinsic clearances to be estimated. The simple or zonal PBPK model provides predictive views on the hepatic removal of drugs and metabolites.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806855     DOI: 10.1016/j.ejps.2006.05.007

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  11 in total

Review 1.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

2.  Modeling and simulation of hepatic drug disposition using a physiologically based, multi-agent in silico liver.

Authors:  Li Yan; Glen E P Ropella; Sunwoo Park; Michael S Roberts; C Anthony Hunt
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

Review 3.  Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.

Authors:  K Sandy Pang; Michael Weiss; Panos Macheras
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

4.  Relationship between drug/metabolite exposure and impairment of excretory transport function.

Authors:  Maciej J Zamek-Gliszczynski; J Cory Kalvass; Gary M Pollack; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922

Review 5.  Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action.

Authors:  Siddharth Sukumaran; Richard R Almon; Debra C DuBois; William J Jusko
Journal:  Adv Drug Deliv Rev       Date:  2010-06-11       Impact factor: 15.470

6.  Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes.

Authors:  Jean-Luc Daire; Benjamin Leporq; Valérie Vilgrain; Bernard E Van Beers; Sabine Schmidt; Catherine M Pastor
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

Review 7.  Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels.

Authors:  Kyoung Ah Min; Xinyuan Zhang; Jing-yu Yu; Gus R Rosania
Journal:  Biopharm Drug Dispos       Date:  2013-12-10       Impact factor: 1.627

8.  Simulating microdosimetry in a virtual hepatic lobule.

Authors:  John Wambaugh; Imran Shah
Journal:  PLoS Comput Biol       Date:  2010-04-22       Impact factor: 4.475

9.  Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry.

Authors:  Yu-Qi He; Li Yang; Yong Liu; Jiang-Wei Zhang; Jun Tang; Juan Su; Yuan-Yuan Li; Yan-Liu Lu; Chang-Hong Wang; Ling Yang; Zheng-Tao Wang
Journal:  Acta Pharmacol Sin       Date:  2009-09-21       Impact factor: 6.150

10.  The use of PBPK modeling across the pediatric age range using propofol as a case.

Authors:  Robin Michelet; Jan Van Bocxlaer; Karel Allegaert; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-08       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.